BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22977269)

  • 21. The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.
    Moon JH; Kim KM; Oh TJ; Choi SH; Lim S; Park YJ; Park DJ; Jang HC
    J Clin Endocrinol Metab; 2017 Jan; 102(1):78-85. PubMed ID: 27754806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy.
    Vera L; Gay S; Campomenosi C; Paolino S; Pera G; Monti E; Mortara L; Seriolo B; Giusti M
    Endokrynol Pol; 2016; 67(4):350-8. PubMed ID: 27387240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
    De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
    Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons.
    Lapauw B; Taes Y; Simoens S; Van Caenegem E; Weyers S; Goemaere S; Toye K; Kaufman JM; T'Sjoen GG
    Bone; 2008 Dec; 43(6):1016-21. PubMed ID: 18835591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma.
    Reverter JL; Colomé E; Holgado S; Aguilera E; Soldevila B; Mateo L; Sanmartí A
    Endocrine; 2010 Jun; 37(3):467-72. PubMed ID: 20960170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
    Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
    Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI).
    Van Caenegem E; Wierckx K; Taes Y; Schreiner T; Vandewalle S; Toye K; Lapauw B; Kaufman JM; T'Sjoen G
    Eur J Endocrinol; 2015 Feb; 172(2):163-71. PubMed ID: 25550352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism.
    Lecomte P; Lecureuil N; Osorio-Salazar C; Lecureuil M; Valat C
    Thyroid; 1995 Feb; 5(1):19-23. PubMed ID: 7787428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
    Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
    Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effects of levothyroxine replacement therapy on bone and mineral metabolism in patients with hypothyroidism].
    Chai R; Ye Z; Zhan Z; Liu W; Yu M; Liu Y
    Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):18-21. PubMed ID: 11798620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.
    Frusciante V; Carnevale V; Scillitani A; Zingrillo M; Dicembrino F; Giannatempo GM; Ghiggi MR; Minisola S
    Eur J Nucl Med; 1998 Feb; 25(2):139-43. PubMed ID: 9473261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter.
    Wesche MF; Tiel-V Buul MM; Lips P; Smits NJ; Wiersinga WM
    J Clin Endocrinol Metab; 2001 Mar; 86(3):998-1005. PubMed ID: 11238476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bone density in differentiated cancer of the thyroid gland treated by hormone-suppressive therapy. Study based on 51 cases].
    Eulry F; Bauduceau B; Lechevalier D; Magnin J; Crozes P; Flageat J; Gautier D
    Rev Rhum Mal Osteoartic; 1992 Apr; 59(4):247-52. PubMed ID: 1496271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of suppressive thyroxine therapy in nodular goiter in postmenopausal women and 2 year's bone mineral density change.
    Chen CY; Chen ST; Huang BY; Hwang JS; Lin JD; Liu FH
    Endocr J; 2018 Nov; 65(11):1101-1109. PubMed ID: 30158361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].
    Khmara IM; Tolkachev IuV
    Klin Med (Mosk); 2005; 83(10):61-5. PubMed ID: 16320850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body composition changes in patients with differentiated thyroid cancer after iodine-131 treatment and short-term levothyroxine replacement and suppression therapy.
    Wang R; Qin S; Qiao T; Jiang W; Tong J; Lu G; Gao D; Zhang M; Lv Z; Li D; Chai L
    Hormones (Athens); 2024 Jun; 23(2):257-265. PubMed ID: 38277093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome.
    Bechtold S; Dalla Pozza R; Putzker S; Roeb J; Buckel M; Weissenbacher C; Schmidt H
    J Pediatr Adolesc Gynecol; 2012 Jun; 25(3):175-80. PubMed ID: 22260890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.